治疗前吻侧前扣带皮层θ活动与抑郁症状改善的关系:一项随机临床试验
该多中心随机对照试验纳入248例慢性或复发性重性抑郁障碍门诊患者,随机接受舍曲林或安慰剂治疗8周。治疗前及第1周较高的吻侧前扣带皮层θ活动可预测更大的抑郁症状改善,且不受治疗分组影响,提示其可能为非特异性预后标志物。
要点
- 治疗前rACCθ活动较高与抑郁症状改善更大相关,且独立于临床和人口学变量。
- 该预测效应不受舍曲林或安慰剂分组影响,提示为非特异性预后标志物。
- rACCθ标志物联合临床变量可解释症状变化方差的39.6%,其中8.5%归因于该标志物。
核心结论
- 治疗前较高的吻侧前扣带皮层θ活动是非特异性的治疗结局预后标志物。
- 这是首项证明rACCθ活动具有增量预测效度的研究。
研究设计与样本
- 筛查634例,随机296例接受舍曲林或安慰剂治疗8周,266例有脑电图记录,248例脑电图数据可用并纳入意向性分析。
主要发现
- 248例可用脑电图数据者中,女性160例(64.5%),男性88例(35.5%),平均年龄36.75岁(SD 13.15)。
- 基线rACCθ活动较高预测抑郁症状改善更大(b=-1.05;95%CI,-1.77至-0.34;P=.004)。
- 第1周rACCθ活动较高同样预测症状改善更大(b=-0.83;95%CI,-1.60至-0.06;P<.04)。
- 上述效应在控制既往与治疗结局相关的临床和人口学变量后仍存在,且不受治疗分组调节。
- rACCθ标志物联合临床和人口学变量可解释症状变化方差的39.6%,其中8.5%的方差独归于rACCθ标志物。
关键数值与推荐
- 主要结局为17项汉密尔顿抑郁量表评分,在基线及第1、2、3、4、6、8周评估。
- 干预为8周舍曲林或安慰剂疗程。
- rACCθ活动采用源定位从静息脑电图中提取,记录于基线和试验开始后1周。
临床怎么用
- rACCθ活动可作为抑郁障碍治疗结局的非特异性预后标志物,辅助临床判断。
- 该标志物在临床和人口学变量基础上提供增量预测信息,但尚未推荐用于常规临床决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Major depressive disorder (MDD) remains challenging to treat. Although several clinical and demographic variables have been found to predict poor antidepressant response, these markers have not been robustly replicated to warrant implementation in clinical care. Increased pretreatment rostral anterior cingulate cortex (rACC) theta activity has been linked to better antidepressant outcomes. However, no prior study has evaluated whether this marker has incremental predictive validity over clinical and demographic measures. OBJECTIVE: To determine whether increased pretreatment rACC theta activity would predict symptom improvement regardless of randomization arm. DESIGN, SETTING, AND PARTICIPANTS: A multicenter randomized clinical trial enrolled outpatients without psychosis and with chronic or recurrent MDD between July 29, 2011, and December 15, 2015 (Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care [EMBARC]). Patients were consecutively recruited from 4 university hospitals: 634 patients were screened, 296 were randomized to receive sertraline hydrochloride or placebo, 266 had electroencephalographic (EEG) recordings, and 248 had usable EEG data. Resting EEG data were recorded at baseline and 1 week after trial onset, and rACC theta activity was extracted using source localization. Intent-to-treat analysis was conducted. Data analysis was performed from October 7, 2016, to January 19, 2018. INTERVENTIONS: An 8-week course of sertraline or placebo. MAIN OUTCOMES AND MEASURES: The 17-item Hamilton Rating Scale for Depression score (assessed at baseline and weeks 1, 2, 3, 4, 6, and 8). RESULTS: The 248 participants (160 [64.5%] women, 88 [35.5%] men) with usable EEG data had a mean (SD) age of 36.75 (13.15) years. Higher rACC theta activity at both baseline (b = -1.05; 95% CI, -1.77 to -0.34; P = .004) and week 1 (b = -0.83; 95% CI, -1.60 to -0.06; P < .04) predicted greater depressive symptom improvement, even when controlling for clinical and demographic variables previously linked with treatment outcome. These effects were not moderated by treatment arm. The rACC theta marker, in combination with clinical and demographic variables, accounted for an estimated 39.6% of the variance in symptom change (with 8.5% of the variance uniquely attributable to the rACC theta marker). CONCLUSIONS AND RELEVANCE: Increased pretreatment rACC theta activity represents a nonspecific prognostic marker of treatment outcome. This is the first study to date to demonstrate that rACC theta activity has incremental predictive validity. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01407094.
引用
- Pizzagalli DA, Webb CA, Dillon DG, et al. Pretreatment Rostral Anterior Cingulate Cortex Theta Activity in Relation to Symptom Improvement in Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2018. PMID: 29641834. doi:10.1001/jamapsychiatry.2018.0252
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。